<DOC>
	<DOCNO>NCT02658461</DOCNO>
	<brief_summary>This prospective , non-interventional time motion study evaluate cost healthcare resource utilization associate administration trastuzumab ( Herceptin ) SC IV formulation HER2-positive EBC . This sub-study clinical study MO22982 ( NCT01401166/PrefHer ) .</brief_summary>
	<brief_title>An Observational Time Motion Study Trastuzumab Subcutaneous ( SC ) Intravenous ( IV ) Formulations Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Early Breast Cancer ( EBC )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Participants MO22982 ( PrefHer ) clinical trial consent presence observer record data study administration trastuzumab Members care team responsible management participant MO22982 ( PrefHer ) clinical trial also consent presence observer administration trastuzumab None specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>